A brief from the National Organization for the Reform of Marijuana Laws (NORML) highlights and clinical data and findings recently published by the journal Molecular Autism. It details how European investigators found through placebo-controlled double-blind study that a single 600mg dose of CBDV (cannabidivarin) modulated the functional connectivity in specific regions of Autism Spectrum Disorder (ASD) patients’ brains, toward neurotypical levels.
While this shows potential in managing and mitigating certain symptoms of ASD, more study is needed to determine if administering CBDV can have a direct impact on ASD symptoms, with researchers concluding:
In conclusion, here we show atypical striatal FC [functional connectivity] with regions commonly associated with ASD symptoms. We further provide preliminary proof of concept that, in the adult autistic brain, acute CBDV administration can modulate atypical striatal circuitry towards neurotypical function. Future studies are required to determine whether modulation of striatal FC is associated with a change in ASD symptoms.“Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin“, CONCLUSION
Whether or not we eventually find that CBDV is effective in modulating ASD symptoms in the same way it modulates measurable connectivity is important, but secondary to another plain and exciting truth illustrated here:
The therapeutic effects cannabis hemp are vast, complex, seemingly-benign, and demanding more study.
Let’s share its incredible potential with friends and neighbors when appropriate and continue to push wherever we can for its objective study.